Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

During the last two decades, there has been broad interest in RNA-based technologies for
the development of prophylactic and therapeutic vaccines. Preclinical and clinical trials have …

Despite vaccine availability, influenza remains a substantial global public health concern.
Here, we report interim findings on the primary and secondary objectives of the safety …

The adaptive immune response to influenza virus infection is multifaceted and complex,
involving antibody and cellular responses at both systemic and mucosal levels. Immune …

Here we have generated 3D structures of glycoforms of the spike (S) glycoprotein from
SARS-CoV-2, based on reported 3D structures and glycomics data for the protein produced …

Seasonal influenza viruses cause recurring global epidemics by continually evolving to
escape host immunity. The viral constraints and host immune responses that limit and drive …

The COVID-19 pandemic galvanized the field of virus genomic surveillance, demonstrating
its utility for public health. Now, we must harness the momentum that led to increased …

Influenza remains one of the major public health concerns because it causes annual
epidemics and can potentially instigate a global pandemic. Numerous countermeasures …

Virus-like particles (VLPs) have gained a lot of interest within the past two decades. The use
of VLP-based vaccines to protect against three infectious agents—hepatitis B virus, human …

Background Influenza vaccines require annual readministration; however, several reports
have suggested that repeated vaccination might attenuate the vaccine's effectiveness. We …